Roughly, antibodies to GAD67 are primarily associated with stiff-person syndrome (SPS) and autoimmune polyendocrine syndrome type 1, whereas GAD65 is a dominant autoantigen in type 1 diabetes (T1D) [2,24,25,26,27,28,29]. Here, GAD1 is linked to stiff-person syndrome.